| 5.525 -0.625 (-10.16%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.2 |
1-year : | 9.28 |
| Resists | First : | 7.02 |
Second : | 7.94 |
| Pivot price | 6.18 |
|||
| Supports | First : | 5.52 |
Second : | 4.59 |
| MAs | MA(5) : | 5.85 |
MA(20) : | 6.45 |
| MA(100) : | 5.45  |
MA(250) : | 5.28 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 13.9 |
D(3) : | 14 |
| RSI | RSI(14): 37.4 |
|||
| 52-week | High : | 7.94 | Low : | 3.42 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TLSI ] has closed above bottom band by 11.6%. Bollinger Bands are 21.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.16 - 6.19 | 6.19 - 6.22 |
| Low: | 5.46 - 5.49 | 5.49 - 5.51 |
| Close: | 5.48 - 5.53 | 5.53 - 5.57 |
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
Wed, 14 Jan 2026
TriSalus Life Sciences, Inc. (TLSI) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Tue, 13 Jan 2026
TriSalus Life Sciences reports 60% revenue growth in Q4 2025 By Investing.com - Investing.com Nigeria
Mon, 12 Jan 2026
TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance - Bluefield Daily Telegraph
Mon, 12 Jan 2026
Cancer-focused medical tech firm’s sales jump 60% in latest quarter - Stock Titan
Fri, 09 Jan 2026
Trisalus Life Sciences CFO buys $33,900 in common stock - MSN
Wed, 17 Dec 2025
Canaccord Genuity Maintains TriSalus Life Sciences (TLSI) Buy Recommendation - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 50 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 42.4 (%) |
| Held by Institutions | 19.4 (%) |
| Shares Short | 795 (K) |
| Shares Short P.Month | 637 (K) |
| EPS | -2.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.55 |
| Profit Margin | -98.5 % |
| Operating Margin | -78 % |
| Return on Assets (ttm) | -61.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 57.4 % |
| Gross Profit (p.s.) | 0.67 |
| Sales Per Share | 0.8 |
| EBITDA (p.s.) | -0.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -2.61 |
| PEG Ratio | 0 |
| Price to Book value | -10.24 |
| Price to Sales | 6.86 |
| Price to Cash Flow | -13.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|